VENLAFAXINE BESYLATE Drug Patent Profile

Which patents cover Venlafaxine Besylate, and what generic alternatives are available?

Venlafaxine Besylate is a drug marketed by Almatica and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in VENLAFAXINE BESYLATE is venlafaxine besylate. There are seventy-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the venlafaxine besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Venlafaxine Besylate

A generic version of VENLAFAXINE BESYLATE was approved as venlafaxine besylate by ALMATICA on June 29^th, 2022.

Summary for VENLAFAXINE BESYLATE

US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	1
Patent Applications:	9
DailyMed Link:	VENLAFAXINE BESYLATE at DailyMed

Recent Clinical Trials for VENLAFAXINE BESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alphacait, LLC	Phase 2
Haining Health-Coming Biotech Co., Ltd.	Phase 2

See all VENLAFAXINE BESYLATE clinical trials

Pharmacology for VENLAFAXINE BESYLATE

Drug Class	Serotonin and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for VENLAFAXINE BESYLATE

N06AX	Other antidepressants
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for VENLAFAXINE BESYLATE

VENLAFAXINE BESYLATE is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almatica	VENLAFAXINE BESYLATE	venlafaxine besylate	TABLET, EXTENDED RELEASE;ORAL	215429-001	Jun 29, 2022		RX	Yes	Yes			Y

Expired US Patents for VENLAFAXINE BESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almatica	VENLAFAXINE BESYLATE	venlafaxine besylate	TABLET, EXTENDED RELEASE;ORAL	215429-001	Jun 29, 2022

Premature patent expiration for: VENLAFAXINE BESYLATE

Expiration due to failure to pay maintenance fee

Patent Number	Tradename	Expiration Date
	VENLAFAXINE BESYLATE

International Patents for VENLAFAXINE BESYLATE

See the table below for patents covering VENLAFAXINE BESYLATE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1485344	BESYLATE DE VENLAFAXINE (VENLAFAXINE BESYLATE)
Australia	2003221535	VENLAFAXINE BESYLATE
World Intellectual Property Organization (WIPO)	03082804
South Africa	200406461	Venlafaxine besylate
Argentina	039163	BESILATO DE VENLAFAXINA

VENLAFAXINE BESYLATE Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Venlafaxine Besylate

Introduction to Venlafaxine Besylate

Venlafaxine besylate, commonly known by its brand names such as Effexor and Effexor XR, is an antidepressant that belongs to the class of serotonin-norepinephrine reuptake inhibitors (SNRIs). It is used to treat a variety of mental health conditions, including major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Here’s a detailed look at the market dynamics and financial trajectory of venlafaxine besylate.

Market Growth and Forecast

The venlafaxine market is anticipated to experience steady growth over the coming years. According to market research, the venlafaxine market is expected to grow at a Compound Annual Growth Rate (CAGR) of 4% from 2022 to 2029[1].

By 2032, the market valuation is projected to rise significantly, driven by the increasing prevalence of diverse mental health conditions. The market size was valued at approximately 3.24 USD billion in 2023 and is expected to continue its upward trend[4].

Key Drivers of Market Growth

Several factors are driving the growth of the venlafaxine market:

• Increasing Prevalence of Mental Health Conditions: The rise in the prevalence of anxiety, social anxiety disorder, and depression is a major driver for the expansion of the venlafaxine market[1].
• Growing Geriatric Population: The increasing geriatric population, which is more prone to mental health issues, is another significant factor contributing to market growth[1].
• Rising Healthcare Expenditure: Increased healthcare spending and better healthcare infrastructure, particularly in regions like North America, are boosting the market[1].
• Government Initiatives and Awareness: Growing government initiatives and rising awareness about mental health are also positively impacting the market growth rate[1].

Market Segmentation

The venlafaxine market is segmented based on several criteria:

• Drug Class: Primarily classified as an antidepressant and SNRI[1].
• Application: Used for treating panic disorder, depression, anxiety, social anxiety disorder, and other conditions[1].
• Demographic: Segmented into adult, pediatric, and geriatric populations[1].
• Dosage Form: Available in forms such as tablets, extended-release capsules, extended-release tablets, and others[1].
• Route of Administration: Primarily oral, with other routes also considered[1].
• End-Users: Includes clinics, hospitals, and other healthcare settings[1].
• Distribution Channel: Distributed through hospital pharmacies, retail pharmacies, and online pharmacies[1].

Regional Market Analysis

The venlafaxine market is dominated by North America due to the presence of major key players, high disposable income, and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to show significant growth during the forecast period due to increasing research and development activities and growing government support[1].

Challenges and Restraints

Despite the positive growth trajectory, the venlafaxine market faces several challenges:

• High Cost of the Drug: The cost of venlafaxine can be a significant barrier, especially for those without insurance coverage. Factors such as treatment plan, dosage form, and pharmacy used can affect the cost[5].
• Side Effects: Venlafaxine is associated with side effects such as loss of appetite, diarrhea, headache, nausea, dizziness, and seizures, which can hamper market growth[1].
• Lack of Awareness: Limited awareness about mental health and the availability of treatments like venlafaxine can further challenge the market[1].

Research and Development

The market is expected to benefit from increased research and development activities and strategic collaborations. These efforts are likely to introduce new formulations, improve efficacy, and enhance patient compliance, thereby providing beneficial opportunities for the venlafaxine market[1].

Financial Considerations

The cost of venlafaxine can vary widely based on several factors:

• Insurance Coverage: Patients with insurance may have lower costs due to copays or percentage-based payments. Prior authorization requirements can also affect the price[5].
• Pharmacy and Dosage Form: The choice of pharmacy and the specific dosage form (e.g., immediate-release tablets or extended-release oral capsules) can influence the cost[5].
• Comparison with Desvenlafaxine: The cost of venlafaxine may be higher or lower than desvenlafaxine, depending on individual circumstances such as the condition being treated and insurance coverage[5].

Patient Epidemiology and Response

Studies have shown that patients with late-life depression may have varying response trajectories to venlafaxine. For instance, patients with high baseline depression severity are less likely to respond after 12 weeks of treatment. However, high baseline depression severity alone is not a definitive predictor of treatment nonresponse[2].

Market Trends and Utilization

The overall trend in the pharmaceutical market, including venlafaxine, is influenced by factors such as price inflation, the use of generic drugs, and changes in clinical practice. The increased availability and use of generic drugs have contributed to a decline in cost inflation, which can impact the financial trajectory of venlafaxine[3].

Key Takeaways

• The venlafaxine market is expected to grow at a CAGR of 4% from 2022 to 2029.
• Key drivers include the increasing prevalence of mental health conditions, growing geriatric population, and rising healthcare expenditure.
• The market faces challenges such as high drug costs, side effects, and lack of awareness.
• Research and development activities are expected to provide beneficial opportunities.
• Regional growth is dominated by North America, with Asia-Pacific showing significant potential.

FAQs

1. What are the primary uses of venlafaxine besylate? Venlafaxine besylate is primarily used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

2. What factors influence the cost of venlafaxine? The cost of venlafaxine is influenced by factors such as treatment plan, dosage form, pharmacy used, and insurance coverage.

3. How does the venlafaxine market segment? The venlafaxine market is segmented based on drug class, application, demographic, dosage form, route of administration, end-users, and distribution channel.

4. Which region dominates the venlafaxine market? North America dominates the venlafaxine market due to the presence of major key players and well-developed healthcare infrastructure.

5. What are the potential challenges for the venlafaxine market? Challenges include high drug costs, side effects associated with venlafaxine, and lack of awareness about mental health treatments.

Cited Sources

1. Data Bridge Market Research - Global Venlafaxine Market - Industry Trends and Forecast to 2029.
2. PubMed - Antidepressant Response Trajectories and Associated Clinical Factors in Late-Life Depression.
3. Law Project for Psychiatric Rights - DRUG TREND REPORT 2006.
4. Market Research Future - Venlafaxine Market Size, Growth, Trends, Report 2032.
5. Medical News Today - Venlafaxine cost 2024: Coupons and more.